According to the official website of the National Healthcare Security Administration, on February 9, 2026, a new round of continuous procurement bidding for batches 1 to 8 of national centralized procurement drugs resulted in the tentative selection results. This follow-up procurement involves 316 commonly used drugs from 1 to 8 batches of national centralized procurement, covering 26 treatment fields such as anti infection, anti-tumor, hypoglycemic, hypotensive, lipid-lowering, nervous system, respiratory system, digestive system, etc. 51000 pharmaceutical institutions across the country participated in the bidding process, with a total of 4623 products from 1091 domestic and foreign enterprises participating in the bidding. 4163 products from 1020 enterprises obtained the qualification to be selected. This continuation procurement is the first nationwide unified continuation of chemical drugs organized by the state for centralized procurement. It is jointly led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces, with all provinces participating, achieving standardized and unified procurement rules. Enterprises only need to bid online once, and if selected, they can achieve nationwide sales, greatly reducing bidding costs. The main characteristics are as follows: firstly, the enthusiasm of enterprises to participate is high, and the selected products are diverse and abundant. The vast majority of enterprises with bidding qualifications participate in bidding quotations, with an overall success rate of up to 93%. On average, 14 companies were selected for each variety, with diverse market supply and abundant clinical options. Secondly, there is a high degree of clinical demand matching, and the overall medication used by patients is stable. This follow-up procurement will be based on the quantity reported by the manufacturer. Preliminary statistics show that the matching rate of the demand for the manufacturer reported by medical institutions has reached 88%. The vast majority of the original selected products in clinical use continue to be selected, with a selection rate of 98%, which is beneficial for avoiding medication replacement. Thirdly, the qualification threshold for bidding has been raised, and the quality requirements have become more stringent. On the basis of insisting that the bidding drugs are reference preparations or evaluated for consistency in quality and efficacy, relevant enterprises are further required to have production experience in the same type of drugs, and no record of violating drug production quality management standards in the production line within 2 years, in order to prevent quality risks caused by a lack of production experience and improve the quality stability and reliability of the selected drugs. Fourthly, the expected outcome of the selection is more clear, clearly reflecting the "anti internal competition" orientation. This continuation adopts the inquiry method, mainly based on the highest effective bidding price and inquiry benchmark formed by the previous selected price. The enterprise can accurately calculate the cost-benefit, make rational quotations, and have clear expectations for selection and volume, achieving the effect of stabilizing the selected price and industry expectations. The selection results of this follow-up procurement are expected to be implemented by the end of March 2026, with a procurement cycle until the end of 2028. A longer procurement cycle can provide sustained benefits to patients, bring stable production and sales expectations to the industry, and promote further consolidation of the achievements of national drug procurement organization. (New Society)